The role of the intrinsic FAS pathway in Titanocene Y apoptosis: The mechanism of overcoming multiple drug resistance in malignant leukemia cells

Toxicology in Vitro

Volumn 26, Issue 1, 2012, Pages 119-124

  Kater, L ^a,b   Claffey, J ^c   Hogan, M ^c   Jesse, P ^a   Kater, B ^a   Strauss S ^a   Tacke, M ^c   Prokop, A ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

ALL relapse; Apoptosis; FADD; Multidrug resistance; P gp; Titanocene

Indexed keywords

FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FAS LIGAND; GLYCOPROTEIN P; PROTEIN BCL 2; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; TITANOCENE; VINCRISTINE;

APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESISTANCE; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL; LYMPHOMA; MELANOMA; MUTANT; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DNA FRAGMENTATION; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FAS LIGAND PROTEIN; GENE EXPRESSION PROFILING; HUMANS; LEUKEMIA; ORGANOMETALLIC COMPOUNDS; RNA, MESSENGER; UP-REGULATION; VINCRISTINE;

EID: 84855342125     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2011.09.010     Document Type: Article

References (28)

1. Bannon J.H., Fichtner I., O'Neill A., et al. Substituted titanocenes induce caspase-dependent apoptosis in human epidermoid carcinoma cells in vitro and exhibit antitumour activity in vivo. Br. J. Cancer 2007, 97:1234-1241.
2. Beckhove P., Oberschmidt O., Hanauske A.R., et al. Antitumor activity of Titanocene Y against freshly explanted human breast tumor cells and in xenografted MCF-7 tumors in mice. Anticancer Drugs 2007, 18:311-315.
3. Brozek J., Bryl E., Ploszynska A., et al. P-glycoprotein activity predicts outcome in childhood acute lymphoblastic leukemia. J. Pediatr. Hematol. Oncol. 2009, 31:493-499.
4. Chou T.-C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22:27-55.
5. Dhooge C., De Moerloose B., Laureys G., et al. P-glycoprotein is an independent prognostic factor predicting relapse in childhood acute lymphoblastic leukaemia: results of a 6-year prospective study. Br. J. Haematol. 1999, 105:676-683.
6. Essmann F., Wieder T., Otto A., et al. GDP dissociation inhibitor D4-GDI (Rho-GDI 2), but not the homologous rho-GDI 1, is cleaved by caspase-3 during drug-induced apoptosis. Biochem. J. 2000, 346:777-783.
7. Fichtner I., Pampillon C., Sweeney N.J., et al. Anti-tumor activity of Titanocene Y in xenografted Caki-1 tumors in mice. Anticancer Drugs 2006, 17:333-336.
8. Gustafsson A.B., Gottlieb R.A. Bcl-2 family members and apoptosis, taken to heart. Am. J. Physiol. Cell. Physiol. 2007, 292:45-51.
9. Helmbach H., Rossmann E., Kern M.A., et al. Drug-resistance in human melanoma. Int. J. Cancer 2001, 93:617-622.
10. Herr I., Debatin K.M. Cellular stress response and apoptosis in cancer therapy. Blood 2001, 98:2603-2614.
11. Juo P., Woo M.S., Kuo C.J., et al. FADD is required for multiple signaling events downstream of the receptor Fas. Cell Growth Differ. 1999, 10:797-804.
12. MacFarlane M. Cell death pathways-potential therapeutic targets. Xenobiotica 2009, 39:616-624.
13. Nagata S. Apoptosis by death factor. Cell 1997, 88:355-365.
14. Nicoletti I., Migliorati G., Pagliacci M.C., et al. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods 1991, 139:271-279.
15. Oberschmidt O., Hanauske A.R., Pampillon C., et al. Antiproliferative activity of Titanocene Y against tumor colony-forming units. Anticancer Drugs 2007, 18:317-321.
16. Pieters R., Klumper E., Kaspers G.J., et al. Everything you always wanted to know about cellular drug resistance in childhood acute lymphoblastic leukemia. Crit. Rev. Oncol. Hematol. 1997, 25:11-26.
17. Prokop A., Wieder T., Sturm I., et al. Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo. Leukemia 2000, 14:1606-1613.
18. Srinivas G., Kusumakumary P., Nair M.K., et al. Mutant p53 protein, Bcl-2/Bax ratios and apoptosis in paediatric acute lymphoblastic leukaemia. J. Cancer Res. Clin. Oncol. 2000, 126:62-67.
19. Tillner J., Winckler T., Dingermann T. A simple cytotoxicity assay using the eucaryotic microorganism Dictyostelium discoideum. Pharmazie 1994, 49:759-761.
20. Vilches Troya J. Understanding cell death: a challenge for biomedicine. An. R. Acad. Nac. Med. 2005, 122:631-659.
21. Voisard R., Dartsch P.C., Seitzer U., et al. Cell culture as a prescreening system for drug prevention of restenosis. Vasa Suppl. 1991, 33:140-141.
22. Voss M., Lettau M., Paulsen M., et al. Posttranslational regulation of Fas ligand function. Cell Commun. Signal. 2008, 6:11.
23. Vrooman L.M., Silverman L.B. Childhood acute lymphoblastic leukemia: update on prognostic factors. Curr. Opin. Pediatr. 2009, 21:1-8.
24. Walczak H., Haas T.L. Biochemical analysis of the native TRAIL death-inducing signaling complex. Methods Mol. Biol. 2008, 414:221-239.
25. Webb J.L. Effects of more than one inhibitor. Enzymes and Metabolic Inhibitors 1 1963, 1:487-512.
26. Weber H., Claffey J., Hogan M., et al. Analyses of Titanocenes in the spheroid-based cellular angiogenesis assay. Toxicol. In Vitro 2008, 22:531-534.
27. Wieder T., Essmann F., Prokop A., et al. Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3. Blood 2001, 97:1378-1387.
28. Zhou S.F., Wang L.L., Di Y.M., et al. Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr. Med. Chem. 2008, 15:1981-2039.